Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 16;388(7):662-664.
doi: 10.1056/NEJMc2214314. Epub 2023 Jan 18.

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1

Jessica Miller  1 , Nicole P Hachmann  1 , Ai-Ris Y Collier  1 , Ninaad Lasrado  1 , Camille R Mazurek  1 , Robert C Patio  1 , Olivia Powers  1 , Nehalee Surve  1 , James Theiler  2 , Bette Korber  2 , Dan H Barouch  3
Affiliations

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1

Jessica Miller et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Neutralizing Antibody Responses to Omicron Subvariants.
Panel A shows spike protein sequences for the omicron BA.2, BA.2.75.2, XBB.1, BA.5, BF.7, and BQ.1.1 subvariants; mutations as compared with the WA1/2020 spike protein are shown. Mutations as compared with the BA.2 variant are indicated by gray boxes, and individual subvariant mutations are shown in colored font. The blank cells under Q493R represent reversions to the ancestral amino acid at this position. Panel B shows neutralizing antibody titers by luciferase-based pseudovirus neutralization assays in participants in 2021 at 6 months after the initial BNT162b2 vaccination (before booster) and after receipt of the BNT162b2 booster. In Panels B through D, dots indicate results in individual participants, red bars indicate medians, and factor differences are shown. The dashed line in each graph indicates the limit of detection. Panel C shows neutralizing antibody titers in participants before and after receipt of a monovalent mRNA booster in 2022, and Panel D shows neutralizing antibody titers in participants before and after receipt of a bivalent mRNA booster in 2022. Neutralizing antibody responses were measured against the WA1/2020 strain and the BA.5, BF.7, BA.2.75.2, BQ.1.1, and XBB.1 variants. The data regarding neutralizing antibodies against the WA1/2020 strain and the BA.5 variant in Panels C and D are from a separate study and are included here for comparison.
See this image and copyright information in PMC

References

    1. Barouch DH. Covid-19 vaccines — immunity, variants, boosters. N Engl J Med 2022;387:1011-1020. - PMC - PubMed
    1. Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 2022;387:86-88. - PMC - PubMed
    1. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 2022;608:603-608. - PMC - PubMed
    1. Collier AY, Miller J, Hachmann NP, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med 2023;XXX:XXX-XXX. - PMC - PubMed
    1. Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science 2022;377:821-822. - PubMed

Publication types

Supplementary concepts